Richard Durant 9.73K Followers

Summary

COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027.

COMPASS is initially targeting the TRD market, which is large and underserved. SPRAVATO has already established the commercial potential of this market, and COMP360 could benefit from reduced dosing frequency.

Recent industry M&A also validates the commercial potential of psychedelics, although competitive dynamics and reimbursement are key risks.

COMPASS's $433 million cash balance provides substantial runway, while PTSD and adjacent opportunities could offer additional upside.

Wallace Garrison/iStock via Getty Images

COMPASS Pathways' (CMPS) share price is now fairly flat since I previously suggested that imminent commercialization should provide further upside.…